U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation

Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received Issue Notification from the United…

Source